From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

Josh Ludwig is global commercial director at ScaleReady, where he leads a team of scientists that drives new business through ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Strengthening strategic partnerships and expanding client base through North America-Asia manufacturing hubs ■  Targeting ...

The pivotal Phase II trial is testing Allogene’s CAR T candidate cemacabtagene ansegedleucel for large B-cell lymphoma.

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

A ripple effect of the NIH's slashed 2026 budget will be felt throughout the biopharma ecosystem. Young companies must act ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F.

Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...